Competition in pharmaceuticals: more product- than price-oriented?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Drug price dynamics following changes in procurement method in the public healthcare setting in Malaysia.PloS one · 2026
   Article
2. The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022.Pharmaceutical medicine · 2025
   Article
3. Worldwide Research Trends and Regional Differences in the Development of Precision Medicine Under Data-Driven Approach: A Bibliometric Analysis.Journal of multidisciplinary healthcare · 2024
   Article
4. Pharmaceutical pricing in Europe: time to take the right direction.Internal and emergency medicine · 2022
   Article
5. Is greater generic competition also linked to lower drug prices in South Korea?Health economics review · 2020
   Article
6. Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.Frontiers in pharmacology · 2020
   Article
7. Conflict of interest disclosure: striking a balance?The European journal of health economics : HEPAC : health economics in prevention and care · 2019
   Article
8. Precision medicine and monoclonal antibodies: breach of promise?Croatian medical journal · 2019
   Article
9. Pharmaceutical pricing conundrum: time to get rid of it?The European journal of health economics : HEPAC : health economics in prevention and care · 2018
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as